Jaro Education Allots 91,696 Equity Shares Under ESOP Plan 2022

Jaro Institute of Technology Management and Research Limited has completed the allotment of 91,696 equity shares under its Employee Stock Option Plan 2022. The Board of Directors approved this allotment on May 02, 2026, issuing shares with a face value of ₹10 each to eligible employees who exercised their stock options under the scheme. The Managing Director, Sanjay Namdeo Salunkhe, signed the regulatory filing submitted to both BSE Limited and National Stock Exchange of India Limited.

Allotment Details

The share allotment was conducted pursuant to the Jaro Education Employees Stock Option Plan 2022, with shares issued in dematerialized form. The exercise price was set at ₹10 per share with no premium charged. The allotted shares carry the distinctive numbers 2,21,78,692 to 2,22,70,387 (both inclusive) and are identified by ISIN number INE00YJ01010.

Parameter Details Total Shares Allotted 91,696 Face Value ₹10 per share Exercise Price ₹10 per share Premium Nil Issue Type ESOP Allotment Form of Issue Dematerialized

Bonus Share Impact

The allotment figure includes 22,674 bonus shares allocated as tag rights for ESOP Grant 1. These bonus shares stem from the shareholders' resolution dated May 24, 2024, which approved the issuance of bonus shares in the ratio of 1:3. According to Clause 8.8 (Bonus Issue) of the ESOP Scheme, this bonus issuance applies specifically to the first grants allotted on May 02, 2022.

Grant Structure

The Employee Stock Option Plan encompasses two distinct grant phases: ESOP Grant 1 dated 02/05/2022 and ESOP Grant 2 dated 27/07/2024.

Post-Allotment Capital Structure

Following this allotment, Jaro Education's capital structure has been updated significantly. The company now has 2,22,70,387 total issued shares, representing a total issued share capital of ₹22,27,03,870. The shares are listed on both BSE Limited (Script Code: 544534) and National Stock Exchange of India Limited (NSE Symbol: JARO).

Metric Post-Allotment Status Total Issued Shares 2,22,70,387 Total Issued Share Capital ₹22,27,03,870 Lock-in Details Not Applicable Listing Status BSE and NSE

Regulatory Compliance

The allotment was conducted in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and Regulation 10(c) of the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021. The company filed the required statement with BSE and NSE on November 13, 2025, receiving filing numbers 248846 and 51901 respectively.

Jaro Institute of Technology Management and Research Limited has completed the allotment of 2,352 equity shares to eligible employees under its Employee Stock Option Plan 2022. The Board of Directors approved this allotment through a resolution passed on March 25, 2026, as part of the company's employee incentive program.

Share Allotment Details

The allotted shares carry specific characteristics and pricing structure that reflect the company's ESOP framework:

Parameter: Details Number of Shares: 2,352 equity shares Face Value: ₹10 per share Exercise Price: ₹10 per share Premium: Nil Issue Type: ESOP Allotment Share Form: Dematerialized

The allotment encompasses shares from two distinct ESOP grants: ESOP Grant 1 dated May 02, 2022, and ESOP Grant 2 dated July 27, 2024. Notably, the total includes 480 bonus shares allocated as tag rights for ESOP Grant 1, following the shareholders' approval of bonus share issuance in a 1:3 ratio on May 24, 2024.

Impact on Share Capital

Following this ESOP allotment, the company's equity structure has been updated with the following changes:

Metric: Post-Allotment Figure Total Issued Shares: 2,21,78,691 Total Issued Share Capital: ₹22,17,86,910 Distinctive Numbers: 2,21,76,340 to 2,21,78,691 ISIN Number: INE00YJ01010

The newly allotted shares are identical to existing shares in all respects and carry no lock-in restrictions. The company has issued these shares in dematerialized form, eliminating the need for physical share certificates.

Regulatory Compliance

Jaro Education has fulfilled its disclosure obligations under multiple regulatory frameworks. The company filed the required statement under Regulation 10(b) of the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 with both BSE and NSE on November 13, 2025. The filing numbers assigned were 248846 for BSE and 51901 for NSE.

The shares are listed on both BSE Limited (Script Code: 544534) and National Stock Exchange of India Limited (NSE Symbol: JARO). The company has confirmed that no listing fees are payable for this allotment, and the shares will trade alongside existing equity shares without any restrictions.

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.

As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation.

We plan to change that - a technology-led and artificial intelligence enabled platform built for super traders and long term investors.

Disclaimer:

The data and information provided on this website is for general informational and research purposes only. While we strive to ensure that the content is accurate, up-to-date, and reliable, this platform utilizes artificial intelligence (AI) tools to generate, curate, and summarize information. As such, the content may occasionally contain errors, omissions, or outdated information. All users are therefore advised to cross verify the source of the data and information.

This website does not constitute professional, legal, financial, medical, or any other form of licensed advice. Users are encouraged to independently verify any information before relying on it, especially for decisions that may have legal, financial, or personal consequences.

The views, analyses, and summaries presented on this platform may be generated or assisted by AI and do not necessarily reflect the opinions of the website owners, operators, editors, or affiliates.

We make no warranties or representations, express or implied, regarding the completeness, accuracy, reliability, suitability, or availability of the information contained on this website. Any reliance you place on such information is strictly at your own risk.

This website may include links to third-party sources or content. We do not control or endorse the nature, accuracy, or availability of those external sites and are not responsible for any content or damages arising from their use.

By using this website, you acknowledge and agree that the use of AI-generated content involves inherent limitations, uncertainties and inaccuracies, and you accept full responsibility for how you interpret and use the information provided.

We reserve the right to modify, update, or remove content and this disclaimer at any time without prior notice.